<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01274468</url>
  </required_header>
  <id_info>
    <org_study_id>14781</org_study_id>
    <nct_id>NCT01274468</nct_id>
  </id_info>
  <brief_title>Tumor Markers in Lung Cancer</brief_title>
  <official_title>Tumor Markers in Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine if DCAMLK1 can be measured in the endobronchial biopsy&#xD;
      specimens and bronchial washings from patients with lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DCAMLK1 is a Ca2+ - ca/modulin (CaM) - dependent protein kinase that is a marker of stem&#xD;
      cells in colonic crypts. Mutations within the stem cell population are thought to be&#xD;
      responsible for the development of most colorectal carcinomas and studies have shown that&#xD;
      DCAMLK1 is highly expressed in these tumors. Since the lung is an embryological development&#xD;
      of the foregut, we speculate that DCAMLK1 will also be upregulated in lung cancers. The aim&#xD;
      of this pilot study is to determine if DCAMLK1 can be measured in the endobronchial biopsy&#xD;
      specimens and bronchial washings from patients with lung cancer.&#xD;
&#xD;
      This is a prospective study in 10 patients with lung masses suspected to be malignant who are&#xD;
      scheduled for diagnostic bronchoscopy.&#xD;
&#xD;
      Patients with lung masses scheduled for diagnostic bronchoscopy will be included if they can&#xD;
      give informed consent to participate and the diagnostic portion of the bronchoscopy has been&#xD;
      uncomplicated. Patients considered to be at high risk during bronchoscopy because of either&#xD;
      abnormal blood gases (Pco2 &gt; 50 mmHg or PaO2 &lt; 70 mmHg on oxygen) or coagulopathy (platelets&#xD;
      &lt;100,000 or INR &gt; 1.5) will be excluded.&#xD;
&#xD;
      If the preliminary results indicate this is feasible, we will then propose a larger study to&#xD;
      examine DCAMLK1 distribution in normal and cancerous tissue as well as the predictive value&#xD;
      of this biomarker.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of DCAMLK1 in BAL and lung biopsy specimens.</measure>
    <time_frame>After collection and analysis of specimens.</time_frame>
  </primary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Lung Cancer</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Lung biopsy&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Ten patients with an expected age &gt;45 years&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  abnormality on chest x-ray that requires diagnosis and physically capable of&#xD;
             undergoing bronchoscopy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt;45 years&#xD;
&#xD;
          -  Patients with severe abnormalities in blood gases and/or a coagulopathy will be&#xD;
             excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary T Kinasewitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OU Health Sciences Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Humphries A, Wright NA. Colonic crypt organization and tumorigenesis. Nat Rev Cancer. 2008 Jun;8(6):415-24. doi: 10.1038/nrc2392. Epub 2008 May 15. Review.</citation>
    <PMID>18480839</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>May 20, 2010</study_first_submitted>
  <study_first_submitted_qc>January 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2011</study_first_posted>
  <last_update_submitted>August 8, 2012</last_update_submitted>
  <last_update_submitted_qc>August 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Oklahoma</investigator_affiliation>
    <investigator_full_name>Gary Kinasewitz</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

